Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

SLXN

Silexion Therapeutics (SLXN)

Silexion Therapeutics Corporation
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SLXN
DatumZeitQuelleÜberschriftSymbolFirma
29/01/202523h30GlobeNewswire Inc.Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross ProceedsNASDAQ:SLXNSilexion Therapeutics Corporation
29/01/202515h59Business WirePESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology MarketNASDAQ:SLXNSilexion Therapeutics Corporation
28/01/202514h28GlobeNewswire Inc.Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer ModelsNASDAQ:SLXNSilexion Therapeutics Corporation
16/01/202517h04Business WirePESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer TreatmentsNASDAQ:SLXNSilexion Therapeutics Corporation
16/01/202502h00GlobeNewswire Inc.Silexion Therapeutics Announces Pricing of $5.0 Million Public OfferingNASDAQ:SLXNSilexion Therapeutics Corporation
15/01/202522h01GlobeNewswire Inc.Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer ChemotherapiesNASDAQ:SLXNSilexion Therapeutics Corporation
13/01/202513h50GlobeNewswire Inc.Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers SymposiumNASDAQ:SLXNSilexion Therapeutics Corporation
17/12/202415h36Business WirePESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions RisesNASDAQ:SLXNSilexion Therapeutics Corporation
17/12/202412h30GlobeNewswire Inc.Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation DevelopmentNASDAQ:SLXNSilexion Therapeutics Corporation
11/12/202415h22InvestorsHub NewsWireSilexion Is Addressing the MOST COMMON Human Cancer Gene Mutation With RNAi; Recent M&As in the Field Were for Tens of Billions - $SLXNNASDAQ:SLXNSilexion Therapeutics Corporation
10/12/202414h30GlobeNewswire Inc.Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of DirectorsNASDAQ:SLXNSilexion Therapeutics Corporation
22/11/202422h30GlobeNewswire Inc.Silexion Therapeutics Announces 1-for-9 Reverse Share SplitNASDAQ:SLXNSilexion Therapeutics Corporation
20/11/202414h30GlobeNewswire Inc.Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity ConferenceNASDAQ:SLXNSilexion Therapeutics Corporation
01/10/202412h45Business WireSilexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical StudiesNASDAQ:SLXNSilexion Therapeutics Corporation
24/09/202413h30Business WireSilexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic CancerNASDAQ:SLXNSilexion Therapeutics Corporation
09/09/202413h32Business WirePESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven CancersNASDAQ:SLXNSilexion Therapeutics Corporation
15/08/200817h18PR Newswire (US)Sielox Reports Second Quarter Sales Growth of 82.5% and Significant Improvement in Financial PerformanceNASDAQ:SLXN
 Showing the most relevant articles for your search:NASDAQ:SLXN